Traumatic Brain Injury Management and Outcomes

Traumatic brain injury (TBI) encompasses a spectrum of injuries from mild concussions to severe cranial trauma, each demanding a coordinated approach from acute stabilisation through long-term rehabilitation. Initial management prioritises rapid assessment of airway, breathing and circulation alongside neurological evaluation to determine severity. Neuroimaging guides decisions on surgical intervention, while continuous monitoring of intracranial pressure and cerebral perfusion supports targeted therapies to prevent secondary injury. Biomarkers measured in blood and cerebrospinal fluid are increasingly incorporated into clinical protocols to refine prognostic models and tailor treatment intensity. Multidisciplinary rehabilitation addresses physical, cognitive and psychological sequelae, with structured programmes shown to improve functional independence and quality of life. Despite advances in acute care and rehabilitation, outcomes remain variable, influenced by injury mechanism, patient age and access to specialised services. Global efforts now focus on standardising data collection and integrating novel therapies into care pathways to reduce long-term disability and socioeconomic burden.

Research from Nature Portfolio

Measurement of neurofilament light protein (NF-L) in serum has emerged as a highly sensitive biomarker of axonal injury in severe TBI. A single-molecule immunoassay quantifies NF-L levels, which correlate closely with injury severity and outperform traditional markers in predicting 12-month clinical outcome. Serial sampling reveals that rising NF-L concentrations in the early post-injury period reliably identify patients at risk of poor neurological recovery. This development offers a practical tool for stratifying cases in both acute care and clinical trials, enabling precision in prognosis and potential adjustment of therapeutic intensity.

Traumatic Brain Injury Management and Outcomes publication trend

The graph below shows the total number of articles in traumatic brain injury management and outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Biomarker: A measurable biological molecule indicating the presence or severity of injury or disease.

Neurofilament light protein (NF-L): A cytoskeletal axonal protein released into blood after neuronal damage, used as a sensitive indicator of neural injury.

Secondary brain injury: Delayed pathological processes—including inflammation, excitotoxicity and oxidative stress—that follow the initial mechanical insult.

Neutrophil phenotype: A distinctive functional state of neutrophils defined by molecular markers and effector activities in injury or disease contexts.

Ferroptosis: A form of regulated cell death driven by iron-dependent lipid peroxidation, implicated in chronic neuronal and glial damage after TBI.

References

1. FOXO1 reshapes neutrophils to aggravate acute brain damage and promote late depression after traumatic brain injury. Military Medical Research (2024).
2. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Scientific Reports (2016).
3. Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets. Frontiers in Cellular Neuroscience (2019).